Documentos de Académico
Documentos de Profesional
Documentos de Cultura
BENZODIACEPINAS
CLONAZEPAM, ALPRAZOLAM Y ZOLPIDEM
PRODUCTOS ENTREGABLES
PROCEDIMIENTO
1. Desarrollo de pretest y preguntas.
2. Exposicin de docente sobre los 3 frmacos en
23/08/2015
OBJETIVOS DE APRENDIZAJE
MECANISMO DE ACCION DE BZP DIFERENCIARLOS DE LOS
BARBITURICOS
2. DIFERENCIA ENTRE ANSIOLITICO E HIPNOTICO
3. DEPENDENCIA A LAS BENZODIACEPINAS
4. FARMACOS QUE SINERGIZAN A LAS BZP
5. USO CLINICO DE BZP: CONVULSION VS ANSIOLISIS
6. ANTIDOTO DE BZP EN SOBREDOSIS
7. METABOLISMO DE BZP Y SUS INTERACCIONES CON OTROS
FARMACOS
8. CARACTERISTICAS GENERALES DEL LOS FARMACOS DEL
GRUPO "Z"
9. FARMACOCINTICA BSICA DE LOS BZP: METABOLISMO
HEPTICO Y VOLUMEN DE DISTRIBUCION
10. EFECTOS ADVERSOS MS IMPORTANTES DE BZP
(ORIENTADOS A LA TOXICIDAD AGUDA)
1.
23/08/2015
23/08/2015
23/08/2015
23/08/2015
METABOLISMO DE BZP
23/08/2015
23/08/2015
USOS DE BZP + FK
23/08/2015
ANTDOTO DE BZP
FLUMAZENILO
DIAZEPAM
23/08/2015
FRMACOS Z
23/08/2015
FRMACOS Z
Nonbenzodi
azepine
hypnotics
Zaleplon
US trade
name
Sonata
Adult dose
(usual)*
5 to 15 mg
Capsule
5 to 10 mg
Tablet
Sublingual tablet
Oral liquid (each
spray delivers 5
mg)
Ambien
Edluar
Zolpidem
Zolpimist
Zolpidem
Ambien CR
controlled release
6.25 to 12.5 mg
Zolpidem middle
of night
administration
1.75 to 3.5 mg
Eszopiclone
Intermezzo
Lunesta
Preparation
1 to 3 mg
Half-life
(hours)
Indication
Sleep onset
insomnia
Sleep onset
insomnia
Sleep onset
insomnia or sleep
Coated tablet
maintenance
insomnia
Sleep
Dissolvable tablet maintenance
(sublingual)
insomnia (middle
night dose)
Sleep onset
insomnia or sleep
Tablet
maintenance
insomnia
Potential for
drug
interactions
Low
1.4 to 4.5
1.6 to 6.7
1.7 to 8.4
Low to moderate
Zolpidem
1.4 to 4.5,
sustained release is metabolized in
part by CYP3A4
preparation
1.4 to 6.7
6 to 9
Moderate
Eszopiclone is
metabolized in
part by CYP3A4
23/08/2015
Ramelteon
Doxepin
Rozerem
Silenor
8 mg
3 to 6 mg
Tablet
Sleep onset
insomnia
Tablet
Sleep
maintenance
insomnia
Moderate.
Ramelteon is
metabolized in
part by CYP1A2.
Strong inhibitors
1 to 2.6 (drug); 2
of CYP1A2,
to 5 (active
including most
metabolite)
fluoroquinolones,
may
interact. Use with
fluvoxamine
contraindicated.
Moderate
15 (drug); 31
Doxepin is
(active metabolite) metabolized in
part by CYP2D6
23/08/2015
FRMACOS INSOMNIO